Samuel Rubinstein
Overview
Explore the profile of Samuel Rubinstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhutani D, Liu Y, Chakraborty R, Radhakrishnan J, Lentzsch S, Peters D, et al.
Br J Haematol
. 2024 Sep;
205(5):1860-1865.
PMID: 39239804
Monoclonal Immunoglobulin deposition disease (MIDD) is characterised by deposits of intact monoclonal light chains in the kidney leading to renal dysfunction. In this study, we retrospectively investigated the underlying plasma...
2.
Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, et al.
Eur J Haematol
. 2023 Jun;
111(3):491-498.
PMID: 37382045
Objectives: Patients with multiple myeloma (MM) enrolled in randomized control trials (RCTs) discontinue treatment for various reasons; however, no prior study has analyzed reasons for discontinuation. We performed a systematic...
3.
Bhutani D, Bal S, Rubinstein S
Front Oncol
. 2023 Mar;
13:1163490.
PMID: 36910666
No abstract available.
4.
Hall J, Rubinstein S, Lilly A, Blumberg J, Chera B
Pract Radiat Oncol
. 2022 Sep;
12(6):504-510.
PMID: 36088238
Purpose: Localized amyloidosis is a condition characterized by deposits of fibrillary proteins confined to a single organ. The most common subtype is amyloid light chain amyloidosis, which is caused by...
5.
Meier J, Jensen J, Dittus C, Coombs C, Rubinstein S
Blood Rev
. 2022 Jun;
56:100986.
PMID: 35753868
Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of...
6.
Martin 3rd R, Grant M, Kimani S, Midha S, May J, Patell R, et al.
JCO Oncol Pract
. 2021 Jul;
18(1):e36-e46.
PMID: 34242082
Purpose: COVID-19 challenged medical practice and graduate medical education. Building on previous initiatives, we describe and reflect on the formative process and goals of the Hematology-Oncology Collaborative Videoconferencing Learning Initiative,...
7.
Chen E, Rubinstein S, Soto C, Bombardi R, Day S, Myers L, et al.
PLoS One
. 2020 Jul;
15(7):e0235713.
PMID: 32634163
Immunoglobulin light chain amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis is caused by a misfolded light chain produced by a clonal population of plasma cells. Disease...
8.
Weaver A, Rubinstein S, Cornell R
Front Oncol
. 2020 Jun;
10:815.
PMID: 32509586
Hyperviscosity syndrome is a serious complication associated with high levels of paraproteins in patients with hematological malignancies. Therapeutic advances in disease control may reduce the incidence of hyperviscosity syndrome; however,...
9.
Rubinstein S, Cornell R, Du L, Concepcion B, Goodman S, Harrell S, et al.
Amyloid
. 2017 Aug;
24(3):205-211.
PMID: 28758811
Background And Objectives: Light chain (AL) amyloidosis frequently involves the kidney, causing significant morbidity and mortality. A pathologic scoring system with prognostic utility has not been developed. We hypothesized that...
10.
Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, et al.
Biol Blood Marrow Transplant
. 2017 May;
23(9):1473-1477.
PMID: 28546074
Light chain amyloidosis (AL) results in tissue deposition of misfolded proteins, causing organ dysfunction. In an era of modern therapies, such as bortezomib, reassessment of the benefit of autologous hematopoietic...